267 institutions hold shares in Cytokinetics Incorporated (CYTK), with 3.96M shares held by insiders accounting for 5.57% while institutional investors hold 109.69% of the company’s shares. The shares outstanding are 64.52M, and float is at 63.82M with Short Float at 15.25%. Institutions hold 103.58% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Blackrock Inc. with over 11.61 million shares valued at $241.28 million. The investor’s holdings represent 16.33% of the CYTK Shares outstanding. As of Dec 30, 2020, the second largest holder is BVF Inc. with 4.88 million shares valued at $101.37 million to account for 6.86% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 4.82 million shares representing 6.78% and valued at over $100.2 million, while State Street Corporation holds 6.53% of the shares totaling 4.64 million with a market value of $96.44 million.
Cytokinetics Incorporated (NASDAQ: CYTK) is 16.22% higher on its value in year-to-date trading and has touched a low of $11.93 and a high of $30.14 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CYTK stock was last observed hovering at around $25.13 in the last trading session, with the day’s loss setting it -0.98% off its average median price target of $27.00 for the next 12 months. It is also 51.7% off the consensus price target high of $50.00 offered by 11 analysts, but current levels are -15.0% lower than the price target low of $21.00 for the same period.
Currently trading at $24.15, the stock is 4.68% and 10.72% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.66 million and changing -3.90% at the moment leaves the stock 14.09% off its SMA200. CYTK registered 101.92% gain for a year compared to 6-month loss of 0.67%. The firm has a 50-day simple moving average (SMA 50) of $21.75 and a 200-day simple moving average (SMA200) of $19.95.
The stock witnessed a 22.71% gain in the last 1 month and extending the period to 3 months gives it a 23.47%, and is 6.43% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.65% over the week and 6.61% over the month.
Cytokinetics Incorporated (CYTK) has around 184 employees, a market worth around $1.63B and $55.80M in sales. Distance from 52-week low is 102.43% and -19.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-37.70%).
Cytokinetics Incorporated (CYTK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Cytokinetics Incorporated (CYTK) is a “Buy”. 11 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 1 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Cytokinetics Incorporated is expected to release its quarterly report on 07/29/2021 and quarterly earnings per share for the current quarter are estimated at -$0.59 with sales reaching $6.68M over the same period.The EPS is expected to grow by 6.70% this year, but quarterly earnings will post -48.10% year-over-year. Quarterly sales are estimated to grow 33.30% in year-over-year returns.
Cytokinetics Incorporated (CYTK) Insider Activity
A total of 85 insider transactions have happened at Cytokinetics Incorporated (CYTK) in the last six months, with sales accounting for 47 and purchases happening 38 times. The most recent transaction is an insider sale by HENDERSON JOHN T, the company’s Director. SEC filings show that HENDERSON JOHN T sold 3,333 shares of the company’s common stock on Apr 01 at a price of $23.54 per share for a total of $78474.0. Following the sale, the insider now owns 7410.0 shares.
Cytokinetics Incorporated disclosed in a document filed with the SEC on Mar 22 that Blum Robert I (President & CEO) sold a total of 5,000 shares of the company’s common stock. The trade occurred on Mar 22 and was made at $25.19 per share for $0.13 million. Following the transaction, the insider now directly holds 0.36 million shares of the CYTK stock.
Still, SEC filings show that on Mar 19, GAGE L PATRICK (Director) disposed off 10,000 shares at an average price of $24.45 for $0.24 million. The insider now directly holds 21,762 shares of Cytokinetics Incorporated (CYTK).
Cytokinetics Incorporated (CYTK): Who are the competitors?
The company’s main competitors (and peers) include Eiger BioPharmaceuticals Inc. (EIGR) that is trading 52.95% up over the past 12 months and Ligand Pharmaceuticals Incorporated (LGND) that is 110.50% higher over the same period. Trevena Inc. (TRVN) is 283.16% up on the 1-year trading charts. Short interest in the company’s stock has risen 5.45% from the last report on Feb 11, 2021 to stand at a total of 9.2 million short shares sold with a short interest ratio of 8.19.